Talk:DLL3

Possible target for small-cell lung cancer (SCLC)
Expert Examines Immunotherapy Potential in Small Cell Lung Cancer says "DLL3 is a molecule that is expressed on about two-thirds of SCLCs, and it is actually a functionally active molecule. It’s a NOTCHED ligand that inhibits NOTCH1. That activates CO1, which is a main driver of SCLC. Therefore, Stemcentrx linked a drug to an antibody against DLL3 with a chemotherapy drug and showed that there was a high response rate in the second- and third-line setting of SCLC." rovalpituzumab tesirine - Rod57 (talk) 14:25, 19 May 2016 (UTC)